Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107435 | 1.00 | HDAC9 (0.40) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10122259 | 1.00 | HDAC9 (0.40) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10107416 | 0.91 | HTT (0.40) | HDAC9SMN1; SMN2HTTLMNACHRM2 | |
| SCHEMBL10107429 | 0.88 | SIGMAR1 (0.39) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10107427 | 0.88 | SIGMAR1 (0.39) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10107428 | 0.88 | SIGMAR1 (0.39) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10107410 | 0.87 | SLC6A4 (0.44) | HDAC9OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL10107451 | 0.84 | HDAC9 (0.40) | HDAC9OPRM1OPRL1SMN1; SMN2HTT | |
| SCHEMBL10107407 | 0.82 | HDAC9 (0.42) | HDAC9SMN1; SMN2LMNANPSR1 | |
| SCHEMBL1753719 | 0.82 | AKR1C1 (0.41) | HDAC9HTTLMNAHDAC4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | PNLIP, APOB, LIPC | HDAC9 2506/4885OPRM1 2897/4885OPRL1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.